[Shenlian Bio: The Phase II clinical trial of UB-221 for the treatment of chronic spontaneous urticaria has reached the primary endpoint] On September 20, Shenlian Biotech (688098.SH) announced that the Phase II clinical study of UB-221 injection, a Class 1 biologic drug independently developed by Shizhiyuan, a subsidiary of the company controlled by the company, for the treatment of chronic spontaneous urticaria has reached the primary endpoint and achieved positive top-line results. A total of 145 subjects were included in the study. The HSS7=0 response rates at week 12 in each dose group of UB-221 were 54%, 53% and 43% respectively, which were significantly higher than the 11% in the placebo group. In terms of safety, UB-221 was generally well tolerated, and no serious adverse events related to treatment occurred. The above-mentioned matters are not expected to have a significant impact on the company's performance in the short term, and subsequent procedures such as phase III clinical research and new drug marketing applications need to be completed.